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Abstract
Objective and Design: Gliclazide has been associated with a low risk of hypoglycemic episodes and beneficial long-term
cardiovascular safety in observational cohorts. The aim of this study was to assess in a systematic review and meta-analysis
of randomized controlled trials the safety and efficacy of gliclazide compared to other oral glucose-lowering agents
(PROSPERO2013:CRD42013004156)
Data Sources: Medline, EMBASE, Clinicaltrials.gov, Trialregister.nl, Clinicaltrialsregister.eu and the Cochrane database.
Selection: Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change,
incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with
other oral blood glucose lowering drugs. Bias was assessed with the Cochrane risk of bias tool. The inverse variance random
effects model was used.
Results: Nineteen trials were included; 3,083 patients treated with gliclazide and 3,155 patients treated with other oral
blood glucose lowering drugs. There was a considerable amount of heterogeneity between and bias in studies. Compared
to other glucose lowering agents except metformin, gliclazide was slightly more effective (20.13% (95%CI: 20.25, 20.02, I2
55%)). One out of 2,387 gliclazide users experienced a severe hypoglycemic event, whilst also using insulin. There were 25
confirmed non-severe hypoglycemic events (2.2%) in 1,152 gliclazide users and 22 events (1.8%) in 1,163 patients in the
comparator group (risk ratio 1.09 (95% CI: 0.20, 5.78, I2 77%)). Few studies reported differences in weight and none were
designed to evaluate cardiovascular outcomes.
Conclusions: The methodological quality of randomized trials comparing gliclazide to other oral glucose lowering agents
was poor and effect estimates on weight were limited by publication bias. The number of severe hypoglycemic episodes
was extremely low, and gliclazide appears at least equally effective compared to other glucose lowering agents. None of the
trials were designed for evaluating cardiovascular outcomes, which warrants attention in future randomized trials.
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Introduction
At present, metformin is the pharmacological cornerstone for
patients with type 2 diabetes (T2DM) [1]. When metformin does
not suffice or is contra-indicated, the next oral treatment options
are; sulphonylureas (SUs), meglitinides, a-glucosidase inhibitor,
thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhib-
itors, and sodium glucose transporter-2 receptor (SGLT-2)
inhibitors. SUs are the preferred second treatment option in for
example the current NICE guidelines, whereas no specific choices
have been made in the American Diabetes Association and
European Association for the Study of Diabetes (ADA-EASD)
position statement [1,2].
The new Dutch type 2 diabetes management guideline
specifically advises gliclazide as the preferred second treatment
option and not SUs as a group. Specifically advising gliclazide is –
amongst others - based on evidence from observational studies
showing cardiovascular benefits of gliclazide over other SUs [3–8].
Individual SUs express a different selectivity for pancreatic and
myocardial SU receptors; gliclazide seems the most selective with
respect to pancreatic receptor stimulation [7,9]. Non-selective SUs
like glibenclamide also block the myocardial SU receptor, and it is
known that closure of these channels during myocardial ischemia
worsens post-ischemic wall function by shortening the action
potential [10–12]. Haemorheological and fibinolytic properties of
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gliclazide [13], a lower incidence of hypoglycemic events and less
weight gain while using gliclazide were also proposed as
explanations for a possible favorable cardiovascular safety profile
[14]. Furthermore, no dose adjustments appears necessary in case
of impaired renal function [15].
The role of gliclazide in the new Dutch guideline, the presumed
differences between individual SUs, the possibility of a lower
hypoglycemia risk, possible cardiovascular safety benefits together
with the absence of a systematic review or meta-analysis
examining gliclazide specifically, brought us to summarize the
results from randomized studies comparing gliclazide with other
oral glucose lowering agents.
Methods
Protocol
The eligibility criteria, outcomes, main and sensitivity analyses
were pre-specified and published on PROSPERO
(2013:CRD42013004156), see Attachment S1. The presentation
of the methods and results is according to the PRISMA
recommendations (available at www.prisma-statement.org).
Eligibility criteria
A study was considered eligible if it was a randomized controlled
trial that: treated non-pregnant adults (aged 18 or older) with type
2 diabetes; excluded patients during Ramadan; had a study
duration of at least 12 weeks; reported change in glycated
hemoglobin (HbA1c); compared gliclazide with other oral glucose
lowering drugs. Trials comparing gliclazide with placebo, diet,
insulin and rosiglitazone were excluded. The two preparations of
gliclazide (gliclazide regular formulation and gliclazide MR) were
grouped for all analyses.
Data sources and searches
An electronic search without language restrictions was per-
formed in Medline (using PubMed), EMBASE and the Cochrane
Library (April 17 2013). See Attachment S2. for our search strategy.
References list of selected articles were searched. Additional
studies were searched for by hand searching the abstracts of the
2010, 2011 and 2012 annual meetings of the American Diabetes
Association and the European Association for the Study of
Diabetes. Completed but unpublished trials were searched
(January 15, 2013) using websites of public registers of clinical
trials (www.clinicaltrials.gov, www.trialregister.nl and www.
clinicaltrialsregister.eu).
Study selection
Publications retrieved from Medline, EMBASE, and the
Cochrane Library, were imported in reference management
software (www.endnote.com). After removing duplicate results,
two authors (GL and KvH) independently performed the study
selection. Differences between the reviewers were resolved by
consensus with a third author (NK). One reviewer (GL) searched
conference abstracts and trial registries.
Data collection and data items
A data extraction form was designed and two reviewers (GL and
PvD) independently abstracted data; discrepancies were resolved
by consensus (see attachment). From each study, the following
characteristics were extracted; author identification, year of
publication, Clinical Trial number, sample size, type of interven-
tion, duration of intervention, participants’ baseline characteristics;
age, sex, race, diabetes duration, previous treatment, HbA1c, body
weight and pre-specified outcomes of efficacy and safety.
Summary measures - Safety
The primary safety outcome was the number of patients
experiencing at least one severe hypoglycemic event. A hypogly-
cemic event was considered severe when treatment by a third
party was necessary.
Secondary safety outcomes included total number of confirmed
non-severe hypoglycemic events, cardiovascular events and
mortality. A non-severe confirmed event was defined as an event
with symptoms and a glucose measurement with a plasma blood
glucose ,4.0 mmol/L. Cardiovascular events were defined as a
combined endpoint of unstable angina, acute myocardial infarc-
tion, stroke and fatal cardiovascular events.
Summary measures - Efficacy
The primary outcome was change in HbA1c from baseline to
endpoint of the intervention, and its difference with the active
comparator(s). The secondary efficacy outcome was the change in
body weight from baseline to endpoint of the intervention. Time
between baseline and endpoint measurements was considered as a
covariate between studies.
Subgroup analyses
Pre-specified subgroup analyses were planned regarding efficacy
outcomes comparing gliclazide to other SUs/meglitinides, com-
paring gliclazide to other drugs except metformin, comparing
gliclazide use as a second additive step in therapy and studies with
at least 24 weeks follow-up. For the hypoglycemia analysis we
planned a subgroup analysis in studies using a maximum gliclazide
dose of 240 mg.
Missing data and multiple reports
Data from intention to treat (ITT) (all participants randomized)
or modified ITT (all randomized participants who received
intervention and had at least one measurement after baseline)
were used when these were available either in a published paper or
on websites of pharmaceutical companies and trial registries.
In case of missing, incomplete or per protocol (PP) data
regarding the primary and secondary outcomes, the corresponding
authors were contacted (three attempts maximum). In case of not
responding, the pharmaceutical companies, if applicable, were
contacted and ITT or modified ITT data were requested.
In case of multiple reports or companion papers of the same
study (published results of an extension period) outcome data from
the original study were extracted, unless the first report was a
planned interim analysis.
Risk of bias assessment
The Cochrane Collaboration’s risk of bias tool was used to
assess risk of bias [16]. This tool considers the presence of bias
caused by: random sequence generation, allocation concealment,
blinding of participants and personnel, incomplete outcome data
(because of high rate of discontinuation, type of analysis, or
imputation of missing data), selective reporting and a category
‘other forms of bias’. Study registration became mandatory in
2004 [17], with September 13, 2005 as the last date for trials not
registered at inception [18]. Studies without registration after this
period were considered at high risk for selective reporting.
The risk of bias was regarded high in case of the presence of
high bias in any domain, low if all key domains (all domains except
random sequence generation and allocation concealment) were of
low bias, and unclear in all other cases. When only the risk of bias
in the 7th domain (other bias) was unclear it was regarded as low
risk of bias [16,19]. Two authors (GL and PvD) independently
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assessed the risk of bias, when necessary consensus was determined
through help of a third author (GdB).
Synthesis of results
Mean differences between the intervention group and all active
comparator groups with standard deviations (SDs) were calculated
for continuous outcomes with an inverse variance random effects
model. If a specific study did not report standard deviations, this
was calculated from the standard error or the 95% confidence
interval (CIs). For dichotomous outcomes, risk ratios and 95% CIs
were used, again using an inverse variance random effects model.
In the absence of a gliclazide group receiving the maximum
approved dose of 240 mg, data regarding the group receiving the
highest dose were analyzed.
Statistical heterogeneity (I2) values of 30–60% and between 60–
90% represent moderate and considerable heterogeneity, respec-
tively [16]. Potential causes of heterogeneity were explored by
looking at outliers and by performing sensitivity analyses,
excluding reports with high overall risk of bias. Sensitivity analyses
were planned for every outcome based on its overall risk of bias.
All analyses were performed with RevMan 5.1 (Nordic
Cochrane Centre).
Results
In total, 19 studies were included (see figure 1). 18 studies were
retrieved from searching in electronic databases [8,14,20–35] and
one study, including Chinese patients, was selected through
searching Clinicaltrials.gov [36]. No additional completed trials
were retrieved from other sources. The ADVANCE study was not
included because the primary goal of the study was to compare a
strict control (with gliclazide) to conventional treatment (without
gliclazide) and not gliclazide itself [37].
Although some authors or pharmaceutical companies respond-
ed [8,27,29], others either did not respond or did not give priority
to our requests [26,28,30–35] or stated that intention to treat
analyses could not be performed for differences in weight [34,35].
Table 1 summarizes the characteristics of the included studies.
Participants’ baseline characteristics show that the studies were
heterogeneous in design. The durations of the intervention periods
varied between 12 and 104 weeks. All but two studies used the
regular gliclazide formulation [8,29].
The primary end point between studies varied, the most
common endpoint being change in HbA1c. Five studies had a
non-inferiority design [29,30,34–36], four used a 95% confidence
interval, with non-inferiority margins of 0.3% [34], 0.4% [35,36]
and 0.5% [29] and one used a 90%CI with a non-inferiority
margin of 0.2% [30]. All 19 included studies contributed to the
HbA1c analysis; 3,083 patients were randomized to gliclazide and
3,155 patients were randomized to another glucose lowering
agent. From the studies that reported sponsoring, almost all were
sponsored by a pharmaceutical company [27,28,30–36].
Gliclazide was compared to other SUs/meglitinides in eight
studies [8,14,20,21,27,29,33,36], to metformin in four studies
[22,23,25,28], to pioglitazone in four studies [28,30–32], to DPP-4
inhibitors in two studies [34,35] and to an a-glucosidase inhibitor
in two studies [24,26]. One study compared gliclazide to both
metformin and pioglitazone [28].
In 12 studies [8,22,23,26,27,29,31–36] severe hypoglycemia,
and in 7 studies [8,14,22,23,26,34,35] non-severe confirmed
hypoglycemia could be evaluated.
Eight studies contributed to the weight analysis. Two studies
with metformin [23,25], one with glibenclamide [20], one with
nateglinide [33], one with acarbose [26], one with pioglitazone
[32] and 2 studies with repaglinide as a comparator [27,36].
None of the trials was designed to assess cardiovascular safety
and/or efficacy. In two larger studies, comparing gliclazide with
glimepiride and pioglitazone respectively, specification of cardio-
vascular events was not possible. Therefore, they were not
included in the meta-analysis [29,30].
Risk of bias
Overall risk of bias for the primary outcome was low in one
study [29], unclear in one [24] and high in all others (see
Attachment S3 and S4).
Few studies described differences in weight with SD’s for the
ITT or modified ITT populations [20,23–27,32,33,36]. The two
studies with DPP-4 inhibitors were at high risk for incomplete
outcomes (exclusion bias) [34,35]. In both cases the PP analysis of
weight were in favor of vildagliptin users [34,35]. ITT data were
not handed over. The study on nateglinide was subject to selective
reporting by not reporting differences in weight and was also
subject to a high risk of attrition bias [33]. In two studies,
pioglitazone was accompanied with a higher weight increase
compared to gliclazide users without making formal comparisons
[30,31]. Two studies with pioglitazone were at high risk for
attrition bias [30,31]. One pioglitazone study also had a high risk
for detection bias [31]. Four large studies were published after
2005 [32–35]. These four studies were either not registered
[32,33] or not appropriately registered (before start of the
recruitment phase) [34,35] and were regarded at high risk for
selective reporting (outcome bias).
Severe hypoglycemia
In those studies, in which severe hypoglycemic events were
systematically reported, there was one severe hypoglycemic event
in 2,387 gliclazide users and one in the 2,430 patients in the
comparator group [8,22,23,26,27,29,31–36]. The one severe
hypoglycemic event in the gliclazide group occurred in a patient
who also started NPH insulin in the prmonths preceding the
incident [27]; the one severe hypoglycemic event in the
comparator group occurred in a patient using glibenclamide.
Confirmed non-severe hypoglycemia
Symptomatic confirmed hypoglycemia’s could be evaluated in 7
studies [8,14,22,23,26,34,35]. There were 25 hypoglycemic events
(2.2%) in 1,152 gliclazide users and 22 hypoglycemic events (1.8%)
in 1,163 patients in the comparator group (risk ratio 1.09 (95% CI:
0.20, 5.78; NS) after 13 to 104 weeks follow-up. There was a high
heterogeneity (I2 77%) across studies.
Three out of 7 studies were responsible for all symptomatic
confirmed hypoglycemic events [14,34,35]. Two studies compar-
ing gliclazide with vildagliptine had a relative long follow-up
period of 52 and 104 weeks and used a gliclazide dose of up to
320 mg, well above the official maximum of 240 mg [34,35]. One
small study comparing with glibenclamide showed 12 confirmed
symptomatic hypoglycemic events in the glibenclamide group and
0 in the gliclazide group [14]. After excluding studies that used a
dose above 240 mg, there were no symptomatic confirmed
hypoglycemic events in 129 gliclazide users, these studies had a
follow-up period between 13 and 26 weeks [14,22,23,26].
One study, with low risk of bias, comparing gliclazide (XR
120 mg) with glimepiride showed an advantage regarding non-
severe, confirmed symptomatic and confirmed asymptomatic
hypoglycaemia episodes in favour of gliclazide. 15 patients
experienced a hypoglycaemic episode in 403 gliclazide users
compared to 39 patients in 439 glimepiride users (p,0.02) [29].
Gliclazide in Randomized Trials
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This study was excluded from the meta-analysis because
asymptomatic episodes were also included in the study analysis
(despite registered glucoses ,3.0 mmol/L) [29].
Glycemic efficacy
Compared to all other interventions, gliclazide was more
effective: 20.12% (95%CI: 20.23, 20.01) on the primary
outcome measure; change in HbA1c from baseline (see Figure 2).
There was moderate heterogeneity with I2 of 48%. The study by
Kardas [8] and the study by Harrower [20] were mainly
responsible for the heterogeneity. After excluding these studies,
the effect estimates were 20.09 (95%CI: 20.18, 20.00).
After excluding 3 studies [22,23,25] that used metformin as
comparator arm and the metformin comparator arm of the study
by Lawrence [28], gliclazide was more effective: 20.13% (95%CI:
20.25, 20.02, I2 55%).
In the 12 studies where the risk for severe hypoglycemia could
be evaluated; gliclazide was more effective (20.11% (95%CI:
20.2, 20.01, I2 26%)). When comparing to other SUs, there was
no significant difference in HbA1c: 20.21% (95% CI: 20.46,
0.05, I2 74%). Inclusion of studies with a maximum dose set at
240 mg gliclazide [8,21–23,27,29,33,36] resulted in a non-
significant difference of 20.14% (95%CI 20.34, 0.05, I2 50%),
compared to all other interventions. After excluding studies that
used gliclazide MR, the effect estimate was 20.09% (95%CI:
20.20, 0.02, I2 35%). As second line treatment
[24,27,29,31,33,35], gliclazide was not significantly different to
comparators: HbA1c 20.07% (95%CI: 20.16, 0.01, I2 0%). After
excluding studies with a duration of less than 24 weeks the effect
estimate was20.11% (95%CI:20.21,20.00, I2 38%). Compared
to metformin monotherapy, the effect estimate of gliclazide
monotherapy was 0.26 (95%CI: 20.59, 1.11, I2 0%).
Weight
The difference in weight was 0.47 kg (95%CI 20.75, 1.70) in
favor of the control group with high heterogeneity (I2 87%) among
the studies. The analysis was based on eight studies including 616
patients using gliclazide and 616 for the reference population
[20,23–27,33,36]. The treatment duration varied from 13 to 52
weeks.
When comparing gliclazide to other SUs or metiglinides the
effect estimate was: 20.09 kg (95%CI 21.72, 1.55, I2 87%). This
analysis was based on four studies including 401 patients for
gliclazide and 411 for SU or metiglinides [20,27,33,36].
Figure 1. PRISMA flow diagram. Presentation of the procedure of literature searching and selection with numbers of articles at each stage.
doi:10.1371/journal.pone.0082880.g001
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When comparing gliclazide to metformin the effect estimate was
1.37 kg (95%CI 0.15, 2.60, I2 28%). This analysis was based on
two studies including 45 patients for gliclazide and 48 for
metformin [23,25].
Studies with pioglitazone or DPP-4 inhibitors had a high risk for
selective reporting; further weight comparisons with these
individual drug classes were not performed.
Cardiovascular events and mortality
The incidence of cardiovascular events could be evaluated in 9
studies [8,23,27,28,31–34,36]. There were 11 cases in 1480
gliclazide users and 20 cases in the comparator group of 1508
patients, risk ratio for gliclazide 0.95 (95% CI: 0.57, 1.61).
Information on total mortality and cardiovascular mortality was
available from 17 and 15 studies, respectively. There were 12
deaths in 2500 gliclazide users and 8 deaths in the comparator
group of 2569 patients, risk ratio gliclazide vs. others; 1.50 (95%
CI: 0.62, 3.62) [8,14,20–29,31–36]. The number of cardiovascular
deaths were 3 in 1602 gliclazide users and 7 in 1619 comparator
patients, risk ratio gliclazide 0.81 (95% CI: 0.26, 2.47) [8,14,20–
28,31–34,36].
Discussion
Severe hypoglycemic events caused by gliclazide are extremely
rare and the occurrence of confirmed symptomatic non-severe
hypoglycemic events in gliclazide users could exclusively be
ascribed to studies using a gliclazide dose of 320 mg instead of
the advised maximum dose of 240 mg. Gliclazide probably has
advantages over glimepiride regarding hypoglycemia risk. Glicla-
zide appears to have a non-relevant beneficial effect on glycemic
control compared to other oral glucose lowering agents. There
were no trials investigating cardiovascular effects of gliclazide and
weight comparisons were limited by a low number of trials and
publication bias. The methodological quality of most studies was
poor.
Gliclazide appears to be safe regarding severe hypoglycemia risk
with one severe hypoglycemic event in 2,387 gliclazide users.
Severe hypoglycemias were defined as the primary outcome, since
severe episodes have the most deleterious effects [38]. We
acknowledge that the risk of severe hypoglycemia in the
comparator groups was also very low. This could either suggest
that the risk of severe hypoglycemic events is rare in general, or
that randomized trials are not the best way for evaluating
hypoglycemic risk and that patients in trials represent a highly
selected group.
The maximum dose of gliclazide (regular formulation) between
studies varied from 240 to 320 mg. Two industry-sponsored high
bias trials, both comparing gliclazide to vildagliptine, were
responsible for all symptomatic confirmed non-severe events in
gliclazide users; both used the 320 mg gliclazide dose [34,35]. It
appears that under the condition of not exceeding the 240 mg
dose, gliclazide is safe regarding non-severe confirmed hypogly-
cemic events. One trial comparing gliclazide with glimepiride
showed a definitely lower incidence of confirmed (either symp-
tomatic or not) hypoglycemia events [29]. In patients who are at
risk for hypoglycemic episodes, gliclazide is probably preferable to
glimepiride.
Regarding hypoglycemic events, it should be noted that cut-off
values can have great impact on the event rate [39] and non-
symptomatic confirmed hypoglycemic events were not included in
the meta-analyses because of concerns for overestimation of the
event rate. The definition and recording of hypoglycemic events
between studies differed substantially. Asymptomatic confirmed
hypoglycemic events below for example 3.0 mmol/L could be
relevant and we acknowledge that unconfirmed hypoglycemic
events can be clinically relevant in patients with hypoglycemia
unawareness.
There seemed to be a small benefit of metformin compared to
gliclazide regarding weight although the effect estimate was small.
Most studies either did not report or did not report ITT-analyses
on differences in weight between individual drugs (i.e. pioglitazone
and vildagliptine) and gliclazide, suggesting a high risk for
Figure 2. Forest plot of the main effect outcome. The main effect outcome HbA1c; gliclazide versus other glucose lowering agents.
Metf =metformin, SU is sulphonylurea, Pio is pioglitazone.
doi:10.1371/journal.pone.0082880.g002
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publication bias in the weight analysis. The lack of cooperation by
authors and pharmaceutical companies in providing data after our
request is disconcerting [28,30,31,34,35]. Because of concerns for
bias, weight comparisons between gliclazide and other individual
drug classes, with for example DPP-4 inhibitors, were not
performed.
Results from randomized trails in this review could not be used
to confirm the observed beneficial cardiovascular effects found in
cohort studies. The results regarding cardiovascular end-points
and mortality must be interpreted with caution; none of the trials
were designed to evaluate cardiovascular events, the number of
randomized controlled trials included in the meta-analysis was low
and the number of events was limited. Furthermore, study
duration was relatively short in most cases. Also, a substantial
number of studies did not report on specific adverse events.
Randomized controlled trials are possibly not the best way of
evaluating these adverse events, al least not when not designed for
evaluating such endpoint and not endowed with a sufficiently long
study duration [40].
A considerable amount of heterogeneity in the primary efficacy
analysis was noted. This heterogeneity could be explained by
differences in primary research questions [8], the inclusion of small
studies, the use of different doses of gliclazide and varying use of
diabetes drugs before randomization between studies.
We did not include the ADVANCE study in the meta-analyses.
The ADVANCE investigated intense glucose control with
gliclazide to a strategy with standard glucose control without
gliclazide. Intensive glucose control itself (irrespective of the drug
that is used) is associated with a lower HbA1c, increased risk for
hypoglycemic events, weight increase and probably has beneficial
effects on cardiovascular outcomes [37,41].
Except for non-severe hypoglycemia risk, we were not able to
make clinically relevant recommendations due a low number and
quality of trails. Our conclusions regarding gliclazide as a second
line treatment were not robust, due to a small number of trials.
We did not conduct separate analyses for each comparator class
or looked at within-class difference because of scarcity of data.
Furthermore, we did not conduct sensitivity analyses or meta-
regression to examine the contribution of participants’ baseline
characteristics to the effect estimate of our primary outcome and
did not conduct mixed treatment comparison/network meta-
analysis. Exclusion of trials at high risk of bias in a sensitivity
analysis did not relevantly alter the results of the main analysis,
although this analysis included few trials.
Conclusions
Relative few studies used gliclazide as active comparator despite
years of clinical experience, no need for dose adjustment in renal
dysfunction, low costs and observational studies showing possible
cardiovascular benefits. The risk of severe or confirmed hypogly-
cemia was extremely low with gliclazide. Gliclazide could have a
relative favorable short-term safety profile; specifically compared
to glimepiride, under the condition of not exceeding the maximum
dose of 240 mg, without evidence for a loss of efficacy. The quality
of reporting changes in weight in randomized controlled trials
could benefit from substantial improvements. Although none of
the trials were designed to evaluation cardiovascular end-points,
the possibility of cardiovascular benefits as shown in observational
studies warrants attention in future randomized trials.
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